A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis (C-early)

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate for Inducing and Sustaining Clinical Response in the Treatment of DMARD-Naïve Adults With Early Active Rheumatoid Arthritis

This study is intended to evaluate the efficacy and safety of Certolizumab Pegol (CZP) in combination with Methotrexate (MTX) for sustaining clinical response achieved in study RA0055 Period 1 [NCT01519791]. Subjects entering this study RA0055 Period 2 achieved sustained Low Disease Activity at Week 52 in study RA0055 Period 1.

Study Overview

• Status: Completed
• Conditions: Rheumatoid Arthritis
• Intervention / Treatment: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)

• Study Type: Interventional
• Enrollment (Actual): 359
• Phase: Phase 3

Expanded Access

Available outside the clinical trial. See expanded access record.

Contacts and Locations

Study Locations

• Argentina
  • Buenos Aires, Argentina
    • 276
  • Rosario, Argentina
    • 284
  • San Juan, Argentina
    • 279
  • Tucuman, Argentina
    • 291
• Australia
  • New South Wales
    • Coffs Harbour, New South Wales, Australia
      • 6
  • Queensland
    • Herson, Queensland, Australia
      • 2
    • Maroochydore, Queensland, Australia
      • 1
  • South Australia
    • Woodville South, South Australia, Australia
      • 8
  • Victoria
    • Fitzroy, Victoria, Australia
      • 5
    • Geelong, Victoria, Australia
      • 4
    • Malvern, Victoria, Australia
      • 3
  • Western Australia
    • Perth, Western Australia, Australia
      • 7
• Austria
  • Wien, Austria
    • 50
• Belgium
  • Brussels, Belgium
    • 51
  • Gilly, Belgium
    • 126
  • Kortrijk, Belgium
    • 36
  • Yvoir, Belgium
    • 65
• Canada
  • British Columbia
    • Kelowna, British Columbia, Canada
      • 240
  • Ontario
    • Hamilton, Ontario, Canada
      • 235
  • Quebec
    • Montreal, Quebec, Canada
      • 188
    • Trois-rivieres, Quebec, Canada
      • 194
• Colombia
  • Barranquilla, Colombia
    • 303
  • Bogota, Colombia
    • 272
  • Bogota, Colombia
    • 293
  • Bogota, Colombia
    • 299
  • Bucaramanga, Colombia
    • 297
  • Chia, Colombia
    • 288
  • Medellin, Colombia
    • 271
  • Medellin, Colombia
    • 298
• Czechia
  • Brno, Czechia
    • 108
  • Bruntal, Czechia
    • 124
  • Hradec Kralove, Czechia
    • 38
  • Praha, Czechia
    • 37
• France
  • Le Kremlin Bicetre, France
    • 16
  • Le Mans, France
    • 85
  • Montpellier Cedex 5, France
    • 88
  • Orleans, France
    • 34
  • Strasbourg, France
    • 79
• Germany
  • Bad Doberan, Germany
    • 52
  • Bayreuth, Germany
    • 17
  • Berlin, Germany
    • 113
  • Berlin, Germany
    • 120
  • Erfurt, Germany
    • 89
  • Frankfurt, Germany
    • 70
  • Hamburg, Germany
    • 71
  • Hildesheim, Germany
    • 81
  • Lingen, Germany
    • 127
  • München, Germany
    • 61
  • Planegg, Germany
    • 53
  • Ratingen, Germany
    • 132
  • Rendsburg, Germany
    • 49
  • Rheine, Germany
    • 69
  • Würzburg, Germany
    • 114
  • Zerbst, Germany
    • 59
• Hungary
  • Budapest, Hungary
    • 18
  • Budapest, Hungary
    • 21
  • Eger, Hungary
    • 86
  • Szolnok, Hungary
    • 131
  • Szombathely, Hungary
    • 110
  • Veszprem, Hungary
    • 19
• Ireland
  • Cork, Ireland
    • 33
  • Dublin, Ireland
    • 54
  • Limerick, Ireland
    • 32
• Italy
  • Ferrara, Italy
    • 115
  • Milano, Italy
    • 122
  • Reggio Emilia, Italy
    • 40
  • Roma, Italy
    • 72
  • Verona, Italy
    • 41
• Mexico
  • Durango, Mexico
    • 281
  • Guadalajara, Mexico
    • 286
  • Merida, Mexico
    • 302
  • Mexico D.F., Mexico
    • 292
  • Monterrey, Mexico
    • 280
  • San Luis Potosi, Mexico
    • 294
• Monaco
  • Monaco, Monaco
    • 78
• Netherlands
  • Leiden, Netherlands
    • 42
• Poland
  • Bydgoszcz, Poland
    • 128
  • Elblag, Poland
    • 67
  • Krakow, Poland
    • 99
  • Poznan, Poland
    • 92
  • Torun, Poland
    • 74
  • Warszawa, Poland
    • 100
  • Wroclaw, Poland
    • 44
• Romania
  • Brasov, Romania
    • 58
  • Bucharest, Romania
    • 111
  • Bucharest, Romania
    • 22
  • Bucharest, Romania
    • 25
  • Bucharest, Romania
    • 26
  • Iasi, Romania
    • 24
  • Lasi, Romania
    • 57
• Spain
  • Coruna, Spain
    • 93
  • Madrid, Spain
    • 47
  • Santiago de Compostela, Spain
    • 63
• Sweden
  • Göteborg, Sweden
    • 76
  • Huddinge, Sweden
    • 82
  • Lund, Sweden
    • 106
  • Malmö, Sweden
    • 123
  • Stockholm, Sweden
    • 77
  • Uppsala, Sweden
    • 75
• Switzerland
  • Fribourg, Switzerland
    • 118
  • St. Gallen, Switzerland
    • 68
• United Kingdom
  • Cannock, United Kingdom
    • 125
  • Dudley, United Kingdom
    • 105
  • Leeds, United Kingdom
    • 56
  • London, United Kingdom
    • 121
  • London, United Kingdom
    • 27
  • Sheffield, United Kingdom
    • 80
  • York, United Kingdom
    • 119
• United States
  • Alabama
    • Birmingham, Alabama, United States
      • 209
    • Huntsville, Alabama, United States
      • 170
    • Mobile, Alabama, United States
      • 180
  • Arizona
    • Glendale, Arizona, United States
      • 247
    • Paradise Valley, Arizona, United States
      • 165
    • Paradise Valley, Arizona, United States
      • 234
    • Phoenix, Arizona, United States
      • 243
    • Tucson, Arizona, United States
      • 251
  • California
    • Covina, California, United States
      • 160
    • Hemet, California, United States
      • 257
    • Los Angeles, California, United States
      • 159
    • San Leandro, California, United States
      • 201
    • Upland, California, United States
      • 202
    • Whittier, California, United States
      • 172
  • Florida
    • Fort Lauderdale, Florida, United States
      • 190
    • Jupiter, Florida, United States
      • 196
    • Lake Mary, Florida, United States
      • 238
    • Miami, Florida, United States
      • 232
    • Naples, Florida, United States
      • 213
    • Ocala, Florida, United States
      • 214
    • Orange Park, Florida, United States
      • 237
    • Orlando, Florida, United States
      • 255
    • Palm Harbor, Florida, United States
      • 163
    • Plantation, Florida, United States
      • 166
    • Sarasota, Florida, United States
      • 192
    • Vero Beach, Florida, United States
      • 200
  • Idaho
    • Coeur d'Alene, Idaho, United States
      • 226
  • Illinois
    • Springfield, Illinois, United States
      • 244
  • Indiana
    • South Bend, Indiana, United States
      • 224
  • Iowa
    • Cedar Rapids, Iowa, United States
      • 215
  • Kansas
    • Wichita, Kansas, United States
      • 191
    • Wichita, Kansas, United States
      • 210
  • Maryland
    • Hagerstown, Maryland, United States
      • 177
  • Michigan
    • Kalamazoo, Michigan, United States
      • 199
  • Minnesota
    • Eagan, Minnesota, United States
      • 198
  • Mississippi
    • Tupelo, Mississippi, United States
      • 203
  • Missouri
    • Saint Louis, Missouri, United States
      • 179
  • Nebraska
    • Lincoln, Nebraska, United States
      • 181
  • Nevada
    • Reno, Nevada, United States
      • 256
  • New Hampshire
    • Lebanon, New Hampshire, United States
      • 229
  • New Jersey
    • Clifton, New Jersey, United States
      • 228
  • New Mexico
    • Albuquerque, New Mexico, United States
      • 207
  • New York
    • Brooklyn, New York, United States
      • 176
    • Plainview, New York, United States
      • 242
    • Rochester, New York, United States
      • 227
  • North Carolina
    • Durham, North Carolina, United States
      • 236
  • Ohio
    • Middleburg Heights, Ohio, United States
      • 245
  • Oklahoma
    • Oklahoma City, Oklahoma, United States
      • 241
  • Oregon
    • Portland, Oregon, United States
      • 186
  • Pennsylvania
    • Bethlehem, Pennsylvania, United States
      • 195
    • Duncansville, Pennsylvania, United States
      • 167
    • Wyomissing, Pennsylvania, United States
      • 168
  • South Carolina
    • Charleston, South Carolina, United States
      • 189
    • Columbia, South Carolina, United States
      • 205
  • Tennessee
    • Hendersonville, Tennessee, United States
      • 204
  • Texas
    • Allen, Texas, United States
      • 217
    • Amarillo, Texas, United States
      • 185
    • Austin, Texas, United States
      • 161
    • Corpus Christi, Texas, United States
      • 178
    • Dallas, Texas, United States
      • 162
    • Houston, Texas, United States
      • 184
    • Houston, Texas, United States
      • 206
    • Houston, Texas, United States
      • 223
    • Mesquite, Texas, United States
      • 158
    • Nassau Bay, Texas, United States
      • 175
    • Plano, Texas, United States
      • 249
    • San Antonio, Texas, United States
      • 197
  • Washington
    • Kennewick, Washington, United States
      • 233
  • West Virginia
    • Clarksburg, West Virginia, United States
      • 183
  • Wisconsin
    • Glendale, Wisconsin, United States
      • 174

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

- Those subjects in previous study RA0055 Period 1 who are in sustained LDA (defined as DAS28[ESR] ≤ 3.2 at Weeks 40 and 52) at Week 52 in previous study RA0055 Period 1

Exclusion Criteria:

- Those subjects in previous study RA0055 Period 1 who are NOT in sustained LDA (defined as DAS28[ESR] ≤ 3.2 at Weeks 40 and 52) at Week 52 in previous study RA0055 Period 1

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo + Methotrexate	Biological: Placebo + Methotrexate (MTX); 1 syringe of Placebo every 2 Weeks and MTX. The MTX treatment is to remain between 15-25 mg/week.; Other Names: MTX
Experimental: CZP 200 mg Q2W + Methotrexate	Biological: Certolizumab Pegol + Methotrexate (MTX); Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at dosage strength of 200 mg/ml. On a maintenance dose of 200 mg every 2 Weeks (Q2W) until Week 102. On a maintenance dose of 200 mg every 4 Weeks (Q4W) until Week 102/ Placebo (PBO) 1 syringe every 4 Weeks (Q4W). CZP and PBO administration to be staggered 2 Weeks apart to maintain blind. The MTX treatment is to remain between 15-25 mg/week.; Other Names: MTX; Cimzia; CZP
Experimental: CZP 200 mg Q4W + Methotrexate	Biological: Certolizumab Pegol + Methotrexate (MTX); Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at dosage strength of 200 mg/ml. On a maintenance dose of 200 mg every 2 Weeks (Q2W) until Week 102. On a maintenance dose of 200 mg every 4 Weeks (Q4W) until Week 102/ Placebo (PBO) 1 syringe every 4 Weeks (Q4W). CZP and PBO administration to be staggered 2 Weeks apart to maintain blind. The MTX treatment is to remain between 15-25 mg/week.; Other Names: MTX; Cimzia; CZP

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Subjects With Disease Activity Score [Erythrocyte Sedimentation Rate] (DAS28 [ESR]) <= 3.2 at Week 104 in RA0055 Period 2 Without Flaring	This Outcome Measure includes all subjects that have a DAS28 [ESR] <= 3.2 from the start of RA0055 Period 2 (Week 52 of RA0055 Period 1) to Week 104 in RA0055 Period 2 without flaring.	Week 104 in RA0055 Period 2

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Subjects With Disease Activity Score 28 [ESR] (DAS28 [ESR]) < 2.6 at Week 52 in Previous Study RA0055 Period 1 Who Maintain a DAS28 [ESR] < 2.6 From Week 52 in RA0055 Period 1 Through Week 104 in RA0055 Period 2 Without Flaring	DAS28[ESR] is calculated using the Tender Joint Count (TJC), Swollen Joint Count (SJC) Erythrocyte Sedimentation Rate (ESR in mm/hour), and the Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS in mm) using the following formula: 0.56 x √(TJC) + 0.28 x √(SJC) + 0.70 x lognat (ESR) + 0.014 x PtGADA, where 28 joints are examined and a lower score indicates less disease activity.	From Week 52 in RA0055 Period 1 to Week 104 in RA0055 Period 2
Change From Baseline in Previous Study RA0055 Period 1 in Modified Total Sharp Score (mTSS) to Week 104 in RA0055 Period 2	Van der Heijde modified Total Sharp Score (mTSS) is a methodology to assess the degree of joint damage by quantifying the extent of bone erosions and joint space narrowing for 44 and 42 joints, respectively. The mTSS ranges from 0 to 448, with higher scores representing greater damage.	From Baseline (Week 0) in RA0055 Period 1 to Week 104 in RA0055 Period 2
Change From Week 52 in Previous Study RA0055 Period 1 in Modified Total Sharp Score (mTSS) to Week 104 in RA0055 Period 2	Van der Heijde modified Total Sharp Score (mTSS) is a methodology to assess the degree of joint damage by quantifying the extent of bone erosions and joint space narrowing for 44 and 42 joints, respectively. The mTSS ranges from 0 to 448, with higher scores representing greater damage.	From Week 52 in RA0055 Period 1 to Week 104 in RA0055 Period 2
Percentage of Subjects With Radiographic Non-progression From Baseline in Previous Study RA0055 Period 1 to Week 104 in RA0055 Period 2	Radiographic nonprogression is defined as change in modified Total Sharp Score (mTSS) <= 0.5. Van der Heijde modified Total Sharp Score (mTSS) is a methodology to assess the degree of joint damage by quantifying the extent of bone erosions and joint space narrowing for 44 and 42 joints, respectively. The mTSS ranges from 0 to 448, with higher scores representing greater damage.	From Baseline (Week 0) in RA0055 Period 1 to Week 104 in RA0055 Period 2
Percentage of Subjects With Radiographic Non-progression From Week 52 in Previous Study RA0055 Period 1 to Week 104 in RA0055 Period 2	Radiographic nonprogression is defined as change in modified Total Sharp Score (mTSS) <= 0.5. Van der Heijde modified Total Sharp Score (mTSS) is a methodology to assess the degree of joint damage by quantifying the extent of bone erosions and joint space narrowing for 44 and 42 joints, respectively. The mTSS ranges from 0 to 448, with higher scores representing greater damage.	From Week 52 in RA0055 Period 1 to Week 104 in RA0055 Period 2
Change From Baseline in Previous Study RA0055 Period 1 in the Joint Erosion Score to Week 104 in RA0055 Period 2	Erosions were assessed in 16 locations per hand and 6 joints per foot. Erosions for each hand location were scored from 0 to 5, with 0 indicating no erosion. Scores 1 to 5 may have included combinations of discrete erosion(s) and/or large erosions. Erosions for each foot joint were scored from 0 to 10, with 0 indicating no erosions. The minimum possible total erosion score for all 32-hand joints was 0, the maximum possible erosion score for all 32-hand joints was 160. The minimum possible total erosion score for all 12-feet joints was 0, the maximum possible erosion score for all 12 feet joints was 120. Thus, the minimum possible total erosion score for hands and feet was 0, the maximum possible total erosion score for hands and feet was 280. Higher values represent greater damage.	From Baseline (Week 0) in RA0055 Period 1 to Week 104 in RA0055 Period 2
Change From Week 52 in Previous Study RA0055 Period 1 in the Joint Erosion Score to Week 104 in RA0055 Period 2	Erosions were assessed in 16 locations per hand and 6 joints per foot. Erosions for each hand location were scored from 0 to 5, with 0 indicating no erosion. Scores 1 to 5 may have included combinations of discrete erosion(s) and/or large erosions. Erosions for each foot joint were scored from 0 to 10, with 0 indicating no erosions. The minimum possible total erosion score for all 32-hand joints was 0, the maximum possible erosion score for all 32-hand joints was 160. The minimum possible total erosion score for all 12-feet joints was 0, the maximum possible erosion score for all 12 feet joints was 120. Thus, the minimum possible total erosion score for hands and feet was 0, the maximum possible total erosion score for hands and feet was 280. Higher values represent greater damage.	From Week 52 in RA0055 Period 1 to Week 104 in RA0055 Period 2
Change From Baseline in Previous Study RA0055 Period 1 in the Joint Narrowing Score to Week 104 in RA0055 Period 2	Joint space narrowing (JSN) was assessed in 15 locations per hand and 6 locations per foot. Joint space narrowing for each location was scored from 0 to 4, with 0 indicating no narrowing. The minimum possible score for JSN in all 30 hand joints was 0, the maximum possible score for JSN in all 30 hand joints was 120. The minimum possible score for JSN in all 12 feet joints was 0, the maximum possible score for JSN in all 12 feet joints was 48. Thus, the minimum possible total JSN score for hands and feet was 0, the the maximum possible total JSN score for Hands and feet was 168. Higher values represent greater damage.	From Baseline (Week 0) in RA0055 Period 1 to Week 104 in RA0055 Period 2
Change From Week 52 in Previous Study RA0055 Period 1 in the Joint Narrowing Score to Week 104 in RA0055 Period 2	Joint space narrowing (JSN) was assessed in 15 locations per hand and 6 locations per foot. Joint space narrowing for each location was scored from 0 to 4, with 0 indicating no narrowing. The minimum possible score for JSN in all 30 hand joints was 0, the maximum possible score for JSN in all 30 hand joints was 120. The minimum possible score for JSN in all 12 feet joints was 0, the maximum possible score for JSN in all 12 feet joints was 48. Thus, the minimum possible total JSN score for hands and feet was 0, the the maximum possible total JSN score for Hands and feet was 168. Higher values represent greater damage.	From Week 52 in RA0055 Period 1 to Week 104 in RA0055 Period 2
Percentage of Subjects Meeting the American College of Rheumatology 20 % Response Criteria (ACR20) at Week 104 in RA0055 Period 2	The assessments are based on a 20 % or greater improvement from Baseline in previous study RA0055 Period 1 in the number of tender joints, a 20 % or more improvement in the number of swollen joints, and a 20 % or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).	From Baseline (Week 0) in RA0055 Period 1 to Week 104 in RA0055 Period 2
Percentage of Subjects Meeting the American College of Rheumatology 50 % Response Criteria (ACR50) at Week 104 in RA0055 Period 2	The assessments are based on a 50 % or greater improvement from Baseline in previous study RA0055 Period 1 in the number of tender joints, a 50 % or more improvement in the number of swollen joints, and a 50 % or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).	From Baseline (Week 0) in RA0055 Period 1 to Week 104 in RA0055 Period 2
Percentage of Subjects Meeting the American College of Rheumatology 70 % Response Criteria (ACR70) at Week 104 in RA0055 Period 2	The assessments are based on a 70 % or greater improvement from Baseline in previous study RA0055 Period 1 in the number of tender joints, a 70 % or more improvement in the number of swollen joints, and a 70 % or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).	From Baseline (Week 0) in RA0055 Period 1 to Week 104 in RA0055 Period 2
Percentage of Subjects Meeting the 2011 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) Remission Criteria at Week 104 in RA0055 Period 2	The ACR/EULAR 2011 remission criteria is defined as: Tender Joint Count (TJC) <= 1, Swollen Joint Count (SJC) <= 1, C-Reactive Protein (CRP) <= 1 mg/dl and Patient's Global Assessment of Disease Activity (PtGADA) <= 10 mm.	Week 104 in RA0055 Period 2
Percentage of Subjects With Clinical Disease Activity Index (CDAI) <= 2.8 at Week 104 in RA0055 Period 2	CDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS in mm), and Physician's Global Assessment of Disease Activity - Visual Analog Scale (PhGADA-VAS in mm). 28 joints are examined where a lower score indicates less disease activity.	Week 104 in RA0055 Period 2
Percentage of Subjects With Simplified Disease Activity Index (SDAI) <= 3.3 at Week 104 in RA0055 Period 2	SDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS in mm), Physician's Global Assessment of Disease Activity - Visual Analog Scale (PhGADA-VAS in mm) and C-Reactive Protein (CRP in mg/L). 28 joints are examined where a lower score indicates less disease activity. The SDAI score ranges from 0 to 86, with a negative value in SDAI change from Baseline indicating an improvement from Baseline.	Week 104 in RA0055 Period 2
Percentage of Subjects With Disease Activity Score [Erythrocyte Sedimentation Rate] (DAS28[ESR]) < 2.6 at Week 104 in RA0055 Period 2	DAS28[ESR] is calculated using the Tender Joint Count (TJC), Swollen Joint Count (SJC) Erythrocyte Sedimentation Rate (ESR in mm/hour), and the Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS in mm) using the following formula: 0.56 x √(TJC) + 0.28 x √(SJC) + 0.70 x lognat (ESR) + 0.014 x PtGADA, where 28 joints are examined and a lower score indicates less disease activity.	Week 104 in RA0055 Period 2
Percentage of Subjects Meeting the 2011 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) Remission Criteria Simplified for Clinical Practice at Week 104 in RA0055 Period 2	The 2011 ACR/EULAR remission criteria simplified for clinical practice is defined as: Tender Joint Count (TJC) <= 1, Swollen Joint Count (SJC) <= 1 and Patient's Global Assessment of Disease Activity (PtGADA) <= 10 mm.	Week 104 in RA0055 Period 2
Percentage of Subjects Achieving a Good or Moderate European League Against Rheumatism (EULAR) Response at Week 104 in RA0055 Period 2	Good response is defined as: DAS28[ESR] <= 3.2 and decrease from Baseline by >1.2; moderate response is defined as achievement of one of the following: DAS28[ESR] <= 3.2 and decrease from Baseline > 0.6 and ≤ 1.2; DAS28[ESR] > 3.2 and ≤ 5.1 and decrease from Baseline > 0.6; DAS28[ESR] > 5.1 and decrease from Baseline >1.2. LOCF= Last Observation Carried Forward	From Baseline (Week 0) in RA0055 Period 1 to Week 104 in RA0055 Period 2
Change From Baseline in Previous Study RA0055 Period 1 in Disease Activity Score [Erythrocyte Sedimentation Rate] (DAS28 [ESR]) to Week 104 in RA0055 Period 2	DAS28[ESR] is calculated using the Tender Joint Count (TJC), Swollen Joint Count (SJC) Erythrocyte Sedimentation Rate (ESR in mm/hour), and the Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS in mm) using the following formula: 0.56 x √(TJC) + 0.28 x √(SJC) + 0.70 x lognat (ESR) + 0.014 x PtGADA, where 28 joints are examined and a lower score indicates less disease activity. DAS28[ESR] ranges from 0-10 with higher values representing higher disease activity. A negative value in DAS28[ESR] change from Baseline indicates an improvement from Baseline.	From Baseline (Week 0) in RA0055 Period 1 to Week 104 in RA0055 Period 2
Change From Week 52 in Previous Study RA0055 Period 1 in Disease Activity Score [Erythrocyte Sedimentation Rate] (DAS28 [ESR]) to Week 104 in RA0055 Period 2	DAS28[ESR] is calculated using the Tender Joint Count (TJC), Swollen Joint Count (SJC) Erythrocyte Sedimentation Rate (ESR in mm/hour), and the Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS in mm) using the following formula: 0.56 x √(TJC) + 0.28 x √(SJC) + 0.70 x lognat (ESR) + 0.014 x PtGADA, where 28 joints are examined and a lower score indicates less disease activity. DAS28[ESR] ranges from 0-10 with higher values representing higher disease activity. A negative value in DAS28[ESR] change from Baseline indicates an improvement from Baseline.	From Week 52 in RA0055 Period 1 to Week 104 in RA0055 Period 2
Change From Baseline in Previous Study RA0055 Period 1 in Clinical Disease Activity Index (CDAI) to Week 104 in RA0055 Period 2	CDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS in mm), and Physician's Global Assessment of Disease Activity - Visual Analog Scale (PhGADA-VAS in mm). 28 joints are examined. CDAI ranges from 0-76 with lower scores indicating less disease activity and higher scores indicating higher disease activity. A negative value in CDAI change from Baseline indicates an improvement from Baseline.	From Baseline (Week 0) in RA0055 Period 1 to Week 104 in RA0055 Period 2
Change From Week 52 in Previous Study RA0055 Period 1 in Clinical Disease Activity Index (CDAI) to Week 104 in RA0055 Period 2	CDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS in mm), and Physician's Global Assessment of Disease Activity - Visual Analog Scale (PhGADA-VAS in mm). 28 joints are examined. CDAI ranges from 0-76 with lower scores indicating less disease activity and higher scores indicating higher disease activity.A negative value in CDAI change from Baseline indicates an improvement from Baseline.	From Week 52 in RA0055 Period 1 to Week 104 in RA0055 Period 2
Change From Baseline in Previous Study RA0055 Period 1 in Simplified Disease Activity Index (SDAI) to Week 104 in RA0055 Period 2	SDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS in mm), Physician's Global Assessment of Disease Activity - Visual Analog Scale (PhGADA-VAS in mm) and C-Reactive Protein (CRP in mg/L). 28 joints are examined where a lower score indicates less disease activity. The SDAI score ranges from 0 to 86, with a negative value in SDAI change from Baseline indicating an improvement from Baseline.	From Baseline (Week 0) in RA0055 Period 1 to Week 104 in RA0055 Period 2
Change From Week 52 in Previous Study RA0055 Period 1 in Simplified Disease Activity Index (SDAI) to Week 104 in RA0055 Period 2	SDAI is calculated as the sum of tender joint count (TJC), swollen joint count (SJC), Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS in mm), Physician's Global Assessment of Disease Activity - Visual Analog Scale (PhGADA-VAS in mm) and C-Reactive Protein (CRP in mg/L). 28 joints are examined where a lower score indicates less disease activity. The SDAI score ranges from 0 to 86, with a negative value in SDAI change from Baseline indicating an improvement from Baseline.	From Week 52 in RA0055 Period 1 to Week 104 in RA0055 Period 2
Percentage of Subjects With a Health Assessment Questionnaire- Disability Index (HAQ-DI) ≤ 0.5 at Week 104 in RA0055 Period 2	Normative physical function is defined as HAQ-DI score <= 0.5. The domains of the HAQ-DI are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. The total score ranges from 0 to 3 with lower scores meaning lower disability.	Week 104 in RA0055 Period 2
Percentage of Subjects With Disease Activity Score 28 [Erythrocyte Sedimentation Rate] (DAS28 [ESR]) <= 3.2 at Week 104 in RA0055 Period 2	DAS28[ESR] is calculated using the Tender Joint Count (TJC), Swollen Joint Count (SJC) Erythrocyte Sedimentation Rate (ESR in mm/hour), and the Patient's Global Assessment of Disease Activity - Visual Analog Scale (PtGADA-VAS in mm) using the following formula: 0.56 x √(TJC) + 0.28 x √(SJC) + 0.70 x lognat (ESR) + 0.014 x PtGADA, where 28 joints are examined and a lower score indicates less disease activity.	Week 104 in RA0055 Period 2
Time to Flare From Week 52 in RA0055 Period 1 to Week 104 in RA0055 Period 2	Time to flare, defined as an increase of DAS28[ESR] >= 0.6 above Week 52 DAS28[ESR] level, having a DAS28[ESR] >= 3.2 and judged by the Investigator as due to RA and all three criteria confirmed at an additional visit two weeks thereafter, from Week 52 onwards. Data not available as > 75% of the participants failed to meet flare criteria.	Week 104 in RA0055 Period 2
Change From Baseline in Previous Study RA0055 Period 1 in the Bristol Rheumatoid Arthritis Fatigue- Multidimensional Questionnaire (BRAF-MDQ) Total Score to Week 104 in RA0055 Period 2	BRAF-MDQ total score ranges from 0 to 70 (with higher scores indicating worse fatigue), whereas the score for each dimension is different due to the varied number of questions (0 -22 for physical, 0- 21 for living, 0- 15 for cognition, and 0- 12 for emotion). A negative value in BRAF-MDQ change from Baseline indicates an improvement from Baseline.	From Baseline (Week 0) in RA0055 Period 1 to Week 104 in RA0055 Period 2
Number of Work Days Missed (Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]) at Week 104 in RA0055 Period 2	Number of work days missed in the last month for employed subjects.	Week 104 in RA0055 Period 2
Number of Work Days With Reduced Productivity (Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]) at Week 104 in RA0055 Period 2	Number of work days with reduced productivity in the last month for employed subjects. Only the employed subjects were analyzed.	Week 104 in RA0055 Period 2
Interference With Work Productivity (Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]) at Week 104 in RA0055 Period 2	The Arthritis interference in the last month with work productivity is measured on a scale that ranges from 0 (no interference) to 10 (complete interference) for employed subjects. Only the employed subjects were analyzed.	Week 104 in RA0055 Period 2
Number of Days With no Household Work (Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]) at Week 104 in RA0055 Period 2	Number of days with no household work in the last month.	Week 104 in RA0055 Period 2
Number of Days With Reduced Household Work Productivity (Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]) at Week 104 in RA0055 Period 2	Number of days with reduced household work productivity in the last month.	Week 104 in RA0055 Period 2
Number of Days With Hired Outside Help (Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]) at Week 104 in RA0055 Period 2	Number of days with hired outside help days in the last month.	Week 104 in RA0055 Period 2
Number of Days Missed of Family/Social/Leisure Activities (Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]) at Week 104 in RA0055 Period 2	Number of days missed of family/social/leisure activities in the last month.	Week 104 in RA0055 Period 2
Interference With Household Work Productivity (Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]) at Week 104 in RA0055 Period 2	The Arthritis interference in the last month with household productivity is measured on a scale that ranges from 0 (no interference) to 10 (complete interference).	Week 104 in RA0055 Period 2
Percentage of Subjects Achieving Low Disease Activity (LDA) at Week 104 in RA0055 Period 2	LDA is defined as achieving a Disease Activity Score 28 [Erythrocyte Sedimentation Rate] (DAS28 [ESR]) <= 3.2. DAS28 values range from 2.0 to 10.0 with a higher value indicating a higher disease activity.	Week 104 in RA0055 Period 2

Collaborators and Investigators

• Sponsor: UCB Pharma

Publications and helpful links

General Publications

• Emery P, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, Arendt C, Mountian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Ann Rheum Dis. 2017 Jan;76(1):96-104. doi: 10.1136/annrheumdis-2015-209057. Epub 2016 May 10.
• Weinblatt ME, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, VanLunen B, Ecoffet C, Cioffi C, Emery P. A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. Arthritis Rheumatol. 2017 Oct;69(10):1937-1948. doi: 10.1002/art.40196. Epub 2017 Sep 12.

Study record dates

Study Major Dates

• Study Start: January 1, 2012
• Primary Completion (Actual): July 1, 2015
• Study Completion (Actual): September 1, 2015

Study Registration Dates

• First Submitted: January 19, 2012
• First Submitted That Met QC Criteria: January 26, 2012
• First Posted (Estimate): January 31, 2012

Study Record Updates

• Last Update Posted (Actual): July 31, 2018
• Last Update Submitted That Met QC Criteria: July 4, 2018
• Last Verified: November 1, 2016

More Information

Terms related to this study

• Keywords: Rheumatoid Arthritis; Certolizumab Pegol - Cimzia
• Additional Relevant MeSH Terms: Immune System Diseases; Autoimmune Diseases; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Arthritis; Arthritis, Rheumatoid; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Antirheumatic Agents; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Dermatologic Agents; Reproductive Control Agents; Abortifacient Agents, Nonsteroidal; Abortifacient Agents; Folic Acid Antagonists; Methotrexate; Certolizumab Pegol
• Other Study ID Numbers: RA0055 Period 2; 2011-001729-25 (EudraCT Number)